Citations

Showing 10 of 108083 citations.

Faculty Opinions recommendation of Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids.
Huebert, Robert C.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727772304.793536483 Get It

Immunophenotypic and molecular comparison between allogeneic and autologous graft‐vs‐host disease of the skin: A retrospective study using immunohistochemical and proteomics methods
Lehman, Julia S. , Hashmi, Shahrukh K. , Gibson, Lawrence E. , Litzow, Mark R. , Patnaik, Mrinal S., Lacy, Martha Q. , Dasari, Surendra , Vanderboom, Patrick M. , Meves, Alexander , El-Azhary, Rokea A, Vanderboom, Patrick, Meves, Alexander , Lehman, Julia S , Lazarus, Hillard M. , el‐Azhary, Rokea A. , Hogan, William J. , Patnaik, Mrinal S., Buadi, Francis K.

Mayo Clinic

Journal of Cutaneous Pathology | September 14, 2017 | Volume: 44 | Issue: 12 | Pages: 1087-1091

10.1111/cup.13019 | PMID 28906023 Get It

Factor IX Gene (F9) Genotyping Trends and Spectrum of Mutations Identified: A Reference Laboratory Experience
Botero, Juliana Perez , Coon, Lea M., Majerus, Julie A. , Chen, Dong , Pruthi, Rajiv K. , Perez Botero, Juliana , Chen, Dong

Mayo Clinic

Seminars in Thrombosis and Hemostasis | September 14, 2017 | Volume: 44 | Issue: 03 | Pages: 287-292

10.1055/s-0037-1605567 | PMID 28905352 Get It

AbstractIn hemophilia B (HB), factor IX gene (F9) genotyping is used for molecular confirmation of affected individuals, for carrier testing, to facilitate the identification of those at risk for anaphylaxis/inhibitors (associated with large deletions), and to assist in assigning disease severity. Owing to test costs, optimal test utilization involves pre/post-test counseling and appropriate patient and test selection (e.g., mutation screening [F9MS] vs. known mutation [F9KM] testing). This article aims to review the trends and outcomes of F9-genotyping orders and describe the spectrum of variants identified in a sample of individuals in our reference laboratory. We performed a retrospective review of consecutive orders submitted to the Special Coagulation DNA Diagnostic Laboratory, Mayo Clinic, between 2012 and 2015. A total of 133 orders (38%) were identified for men: 118 (88%) were F9MS and 15 (12%) were F9KM. Thirteen orders (10%) were cancelled. A total of 209 orders were identified for women: 178 (85%) were F9MS and 31 (15%) were F9KM. Thirty-seven orders (18%) were cancelled and 30% of the tests performed yielded negative results. A total of 164 samples (47%) were received without clinical information. Seventeen previously unreported variants were identified. F9 genotyping provides useful information for HB management; however, 18% of our orders were cancelled and almost half were received without relevant clinical information, thus reaffirming the need for ongoing scrutiny of submitted orders. Optimal patient and test selection is important as is the accurate interpretation of variants identified. Most of the pathogenic variants identified were point mutations, with very few large deletions, consistent with the literature.
The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension
Chen, Libo , Larsen, Carolyn , Le, Rachel J., Connolly, Heidi M. , Pislaru, Sorin V. , Murphy, Joseph G. , McGoon, Michael D., Frantz, Robert P. , Kane, Garvan C. , Larsen, Carolyn M , Sabbah, Michael S. , Frantz, Robert P

Mayo Clinic

The Clinical Respiratory Journal | September 14, 2017 | Volume: 12 | Issue: 4 | Pages: 1572-1580

10.1111/crj.12713 | PMID 28905517 Get It

AbstractIntroductionTricuspid valve regurgitation (TR) is a frequent finding in patients with pulmonary arterial hypertension (PAH). However, its prognostic significance and relation to PAH, while suspected, are poorly understood. We assessed 727 consecutive patients with newly diagnosed PAH who underwent transthoracic echocardiographic evaluation of tricuspid valve function.ObjectivesThe study objective was to determine the association of TR presence and severity with patient characteristics, pulmonary artery hemodynamics and outcome.MethodsConsecutive patients with newly diagnosed PAH (N = 727 with group 1 pulmonary hypertension) underwent transthoracic echocardiographic evaluation of tricuspid valve function at diagnosis. The primary study end point was all‐cause mortality or lung transplantation.ResultsIn this population, 702 patients (96.5%) had TR; in 165 patients (23%), TR was severe. Compared with those with no or mild TR by echocardiography criteria, patients with severe TR had shorter mean (SD) 6‐minute walk distances (285 [125] m vs 360 [121] m; P = .02) and higher levels of B‐type natriuretic peptide (695 [672] pg/dL vs 328 [300] pg/dL; P < .05). Severe TR was associated with greater right atrial dilatation (91% vs 47%; P = .004) and right ventricular (RV) dilatation (92% vs 51%; P = .008), greater right atrial pressure (mean [SD] 15 [7] mm Hg vs 10 [6] mm Hg; P < .001) and lower cardiac index (mean [SD], 2.2 [0.7] L/min/m2 vs 2.8 [0.9] L/min/m2; P < .001). Severe TR was strongly predictive of greater 5‐year mortality risk after adjustment for age, sex, functional class, 6‐minute walk distance, diffusing capacity, RV size and pulmonary vascular resistance index (adjusted hazard ratio, 1.83; 95% CI, 1.38‐2.41; P < .001).ConclusionsSevere TR was a significant predictor of long‐term mortality rate in PAH, and TR severity correlated with PAH severity.
Microdosimetric measurements of a clinical proton beam with micrometer‐sized solid‐state detector
Anderson, Sarah , Tran, Linh T. , Chartier, Lachlan, Petasecca, Marco , Lerch, Michael , Prokopovich, Dale A., Reinhard, Mark I., Perevertaylo, Vladimir L. , Rosenfeld, Anatoly , Herman, Michael , Beltran, Chris , Anderson, Sarah E, Furutani, Keith M. , Herman, Michael G., Rosenfeld, A B , Beltran, Chris J , Anderson, Sarah E.

Mayo Clinic

Medical Physics | September 14, 2017 | Volume: 44 | Issue: 11 | Pages: 6029-6037

10.1002/mp.12583 | PMID 28905399 Get It

PurposeMicrodosimetry is a vital tool for assessing the microscopic patterns of energy deposition by radiation, which ultimately govern biological effect. Solid‐state, silicon‐on‐insulator microdosimeters offer an approach for making microdosimetric measurements with high spatial resolution (on the order of tens of micrometers). These high‐resolution, solid‐state microdosimeters may therefore play a useful role in characterizing proton radiotherapy fields, particularly for making highly resolved measurements within the Bragg peak region. In this work, we obtain microdosimetric measurements with a solid‐state microdosimeter (MicroPlus probe) in a clinical, spot‐scanning proton beam of small spot size.MethodsThe MicroPlus probe had a 3D single sensitive volume on top of silicon oxide. The sensitive volume had an active cross‐sectional area of 250 μm × 10 μm and thickness of 10 μm. The proton facility was a synchrotron‐based, spot‐scanning system with small spot size (σ ≈ 2 mm). We performed measurements with the clinical beam current (≈1 nA) and had no detected pulse pile‐up. Measurements were made in a water‐equivalent phantom in water‐equivalent depth (WED) increments of 0.25 mm or 1.0 mm along pristine Bragg peaks of energies 71.3 MeV and 159.9 MeV, respectively. For each depth, we measured lineal energy distributions and then calculated the dose‐weighted mean lineal energy, . The measurements were repeated for two field sizes: 4 × 4 cm2 and 20 × 20 cm2.ResultsFor both 71.3 MeV and 159.9 MeV and for both field sizes, increased with depth toward the distal edge of the Bragg peak, a result consistent with Monte Carlo calculations and measurements performed elsewhere. For the 71.3 MeV, 4 × 4 cm2 beam (range at 80% distal falloff, R80 = 3.99 cm), we measured keV/μm at WED = 2 cm, and keV/μm at WED = 3.95 cm. For the 71.3 MeV, 20 × 20 cm2 beam, we measured keV/μm at WED = 2.6 cm, and keV/μm at WED = 3 cm. For the 159.9 MeV, 4 × 4 cm2 beam (R80 = 17.7 cm), keV/μm at WED = 5 cm, and keV/μm at WED = 17.6 cm. For the 159.9 MeV, 20 × 20 cm2 beam, keV/μm at WED = 5 cm, and keV/μm at WED = 17.6 cm.ConclusionsWe performed microdosimetric measurements with a novel solid‐state, silicon‐on‐insulator microdosimeter in a clinical spot‐scanning proton beam of small spot size and unmodified beam current. For all of the proton field sizes and energies considered, the measurements of were in agreement with expected trends. Furthermore, we obtained measurements with a spatial resolution of 10 μm in the beam direction. This spatial resolution greatly exceeded that possible with a conventional gaseous tissue‐equivalent proportional counter and allowed us to perform a high‐resolution investigation within the Bragg peak region. The MicroPlus probe is therefore suitable for applications in proton radiotherapy.
St. Louis encephalitis virus possibly transmitted through blood transfusion—Arizona, 2015
Venkat, Heather , Adams, Laura E. , Sunenshine, Rebecca, Krow‐Lucal, Elisabeth , Levy, Craig, Kafenbaum, Tammy, Sylvester, Tammy, Smith, Kirk, Townsend, John, Dosmann, Melissa, Kamel, Hany , Patron, Roberto L. , Kuehnert, Matthew J. , Annambhotla, Pallavi , Basavaraju, Sridhar V. , Rabe, Ingrid B., Team, SLEV Transmission Investigation, Patron, Roberto, Townsend, John, Team, SLEV Transmission Investigation

Mayo Clinic

Transfusion | September 14, 2017 | Volume: 57 | Issue: 12 | Pages: 2987-2994

10.1111/trf.14314 | PMID 28905395 Get It

BACKGROUNDSt. Louis encephalitis virus is a mosquito‐borne flavivirus that infrequently causes epidemic central nervous system infections. In the United States, blood donors are not screened for St. Louis encephalitis virus infection, and transmission through blood transfusion has not been reported. During September 2015, St. Louis encephalitis virus infection was confirmed in an Arizona kidney transplant recipient. An investigation was initiated to determine the infection source.STUDY DESIGN AND METHODSThe patient was interviewed, and medical records were reviewed. To determine the likelihood of mosquito‐borne infection, mosquito surveillance data collected at patient and blood donor residences in timeframes consistent with their possible exposure periods were reviewed. To investigate other routes of exposure, organ and blood donor and recipient specimens were obtained and tested for evidence of St. Louis encephalitis virus infection.RESULTSThe patient presented with symptoms of central nervous system infection. Recent St. Louis encephalitis virus infection was serologically confirmed. The organ donor and three other organ recipients showed no laboratory or clinical evidence of St. Louis encephalitis virus infection. Among four donors of blood products received by the patient via transfusion, one donor had a serologically confirmed, recent St. Louis encephalitis virus infection. Exposure to an infected mosquito was unlikely based on the patient's minimal outdoor exposure. In addition, no St. Louis encephalitis virus‐infected mosquito pools were identified around the patient's residence.CONCLUSIONThis investigation provides evidence of the first reported possible case of St. Louis encephalitis virus transmission through blood product transfusion. Health care providers and public health professionals should maintain heightened awareness for St. Louis encephalitis virus transmission through blood transfusion in settings where outbreaks are identified.
Increased Incidence of Loco-Regional Recurrences among African American Women with Terminal Stage Breast Cancer
Colón‐Otero, Gerardo , King, Sherry, Smith, Vandelyn, Bieber, Carolyn, Shannon, Robert P. , Perez, Edith A. , Crook, Julia E. , Solberg, Lawrence A.

Mayo Clinic

Clinical medicine. Oncology | September 14, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmo.s988 | PMID 21892330 Get It

A prospective analysis of women with terminal breast cancer admitted to CHNE from November 2006-August 2007 evaluated anecdotal observations that African American (AA) women are likelier than Caucasian women to evidence loco-regional recurrences (LRR). Women with terminal breast cancer who were admitted to CHNE, a not-for-profit hospice serving over 90% of Northeast Florida hospice patients, were eligible for participation. 134 terminal breast cancer patients were assessed by hospice nurses for LRR presence via chest wall examination. 80% of them (107) were Caucasian, 17% (23) were AA and 3% (4) were of other ethnicities. Evidence of LRR were noted in 13% of the women (17/134). The proportion of patients with LRR was higher in AA women than Caucasian women (26% vs. 10%, 6/23 vs. 11/107, respectively), although this difference was not statistically significant (p = 0.08). The majority of Caucasian women with LRR consented to a medical record review, but a minority of AA women consented (8/11 vs. 2/6, respectively, p = 0.16). Conclusion Evaluating disparities in breast cancer care outcomes is possible by reviewing data from patients served by hospice programs that aid a majority of patients within a community. This pilot data suggests that AA women with breast cancer have a higher incidence of loco-regional failure as a component of their terminal breast cancer disease than Caucasian women. A smaller proportion of AA patients and families agreed to participate in a medical record review study than Caucasians. Larger studies are necessary to confirm these findings, to elucidate factors contributing to disparities and to develop potential solutions.
Response of Cutaneous Metastases from Breast Cancer to Capecitabine
Zahasky, Katie M., Kaur, Judith S. , Sideras, Kostandinos

Mayo Clinic

Clinical medicine. Oncology | September 14, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmo.s521 | PMID 21892308 Get It

Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E
Katipamula, Rajini, Jatoi, Aminah , Foster, Nathan R. , Nichols, Francis, Rubin, Joseph, Callister, Matthew D., Gunderson, Leonard L., Nichols, Francis C., Alberts, Steven R.

Mayo Clinic

Clinical medicine. Oncology | September 14, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmo.s444 | PMID 21892283 Get It

Purpose This brief report describes a planned, interim, 6-patient toxicity analysis that confirms the safety of pemetrexed, carboplatin, radiation with subsequent surgery, as prescribed in the North Central Cancer Treatment Group trial N044E, in patients with locally advanced esophageal cancer. Methods Six patients with locally advanced, potentially resectable esophageal cancer received pemetrexed 500 mg/m 2 and carboplatin AUC = 6 on days 1 and 22 with 5040 centigray of concomitant radiation in 28 fractions over 5.5 weeks followed by esophagectomy as a prelude to a phase II multi-institutional trial. Results Only 1 of the 6 patients experienced a grade 4 adverse event (neutropenia). This patient also experienced a grade 3 depression. Of the remaining 5 patients, three experienced at least one grade 3 adverse event (neutropenia, nausea/vomiting, and esophagitis). There were no deaths. Incidentally, one patient manifested a complete pathologic response, three a partial pathologic response, and one stable disease. Conclusion These preliminary observations on safety suggest that this regimen can be further studied in this clinical setting.
Thiamine content of F‐75 therapeutic milk for complicated severe acute malnutrition: time for a change?
Hiffler, Laurent , Adamolekun, Bola, Fattal‐Vavleski, Aviva, Fischer, Philip R.

Mayo Clinic

Annals of the New York Academy of Sciences | September 14, 2017 | Volume: 1404 | Issue: 1 | Pages: 20-26

10.1111/nyas.13458 | PMID 28905406 Get It

AbstractSince community‐based management of severe acute malnutrition has become the standard of care, the clinical profile of severe acutely malnourished patients admitted to hospitals or inpatient therapeutic feeding centers has changed significantly. These patients are usually very ill and often present with several comorbidities, such as shock, sepsis, and pneumonia. Complicated severe acute malnutrition patients are at risk of thiamine insufficiency, and critically ill patients have higher thiamine requirements. The thiamine content of F‐75, the therapeutic milk formula used in the early stabilization phase of refeeding in patients with severe acute malnutrition, seems insufficient. Here, we discuss the need and rationale for a substantial increase in the thiamine content of F‐75.